J. Peter A. Yhip, MD, FACC

Doctor Yhip
Logo Amarillo Heart Institute



Amarillo Heart Institute

Founder Partner


Texas Cardiovascular Center (TCC)

Founder & Partner


  • B.S. Physics, University of California Riverside, Riverside, CA. (1987)
  • Doctor of Medicine, Loma Linda University School of Medicine, Loma Linda, CA. (1991)


  • Rotating Internship, Santa Clara Valley Medical Center, San Jose, CA. (06/1991 – 06/1992)
  • Resident, Radiation Oncology, University of Texas – MD Anderson Cancer Center Houston, TX. (06/1992 – 07/1993)
  • Resident, Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, CA. (06/1993 – 06/ 1996) 


  • Interventional Cardiovascular Fellowship with Drs. Gerald Dorros, and Nathan Laufer at Arizona Heart Institute and Good Samaritan Hospital, Phoenix, AZ. (07/1999 – 06/2000) 
  • Cardiology Fellowship, University of Texas, Houston Health Sciences Center, Hermann Hospital, Houston, TX. (07/1996 – 06/1999)

Professional experience

  • General & Interventional Cardiovascular Medicine  , Amarillo Heart Group, Amarillo, TX. (08/2021 – Present)
  • General & Interventional Cardiovascular Medicine. Partner, North State Cardiology, Chico, CA. (08/2006 – 08/2021)
  • General & Interventional Cardiovascular Medicine. Locum Tenens. (03/2005 – 07/2006)
  • General & Interventional Cardiovascular Medicine. Hillsboro Cardiology, Hillsboro, OR. (04/2002 – 12/2004)
  • General & Interventional Cardiovascular Medicine. Olympia Multispecialty Clinic, Olympia, WA. (08/2000 –03/2002)
  • Past Director, Medical ICU & DCU (step down telemetry), Enloe Medical Center.

Hospital Affiliations

  • Baptist St. Anthony’s Health System, Amarillo, TX. (2021 – Present)
  • Northwest Texas Healthcare System, Amarillo, TX. (2021 – Present)


  • Amarillo Heart Institute, Amarillo, TX.
  • Texas Cardiovascular Center, Amarillo, TX.

Board Certification (s)

  • Fellow of the American Board of Internal Medicine, Interventional Cardiovascular Diseases.
  • Fellow of the American Society of Nuclear Cardiology. 
  • Fellow of the National Board of Medical Examiners, Part I, Part II, Part III.
  • Fellow of the American Board of Internal Medicine, Internal Medicine.


  • Chief Cardiology Fellow, UT Houston Health Sciences Center.
  • Bristol-Myers Squibb Cardiology Fellows Abstract Award. (American College of Cardiology Sessions) 
  • Solomon Scholars Resident Research Award, Cedars-Sinai Medical Center – UCLA, Los Angeles, CA. 
  • Alpha Omega Alpha, Epsilon Chapter, California.
  • Walter E. MacPherson Society Outstanding Student Researcher – Basic Sciences Loma Linda University, Loma Linda, CA.

Publications & Abstracts

Balloon to artery ratio, not inflation pressure, correlates with adequate stent deployment: size is  more important than pressure. Fujise K, Yhip P, Anderson HV, Schroth G, Rosales O, Smalling  RWS. J Interven Cardiol.

Intracoronary adenosine administered during rotational atherectomy of complex lesions in native  coronary arteries reduces the incidence of “no reflow” phenomenon. Hanna GP, Yhip P, Fujise K,  Schroth GW, Rosales OR, Anderson HV, Smalling RW. Catheterization and Cardiovascular  Interventions 48:275-278, 1990

Primary Stenting in Acute Myocardial Infarction. Yhip JPA, Smalling RW. Thrombosis and  Haemostasis 82(Suppl)

Topographic organization of the retinocollicular projection in the neonatal rat. Yhip JPA, Kirby MA.  Visual Neuroscience.

Primary angioplasty improves outcome in right ventricular infarction. Rosales OR, Schroth GW,  Yhip P, Thiessen, Anderson HV, Fujise K, Smalling RW. Presented in poster form: 1998 ACC  Scientific Session.

Type B termination of ventricular fibrillation after a stimulus given in the protective zone. Yhip JPA,  Hwang C, Kamjoo K, Karagueuzian HS, Chen PS. Presented in oral form: 1996 NASPE Scientific Session.

Geometric remodeling predominantly accounts for luminal loss in rabbit iliac artery injury model: A  serial intravascular ultrasound study. Makkar RR, Sheth S, Yhip P, Luo H, Fishbein MC, Dev V,  Eigler NL, Litvack FI. Presented in poster form: 1995 AHA Scientific Sessions.

Reduced serum paraoxonase activity is associated with progression of atherosclerosis and new clinical events: Bezafibrate coronary atherosclerosis intervention trial. Regnstrom J, Nilsson, Yhip  P, Cercek B, de Faire U, Ericson CG, Kaul S, Hamsten A, Shah PK. Presented in oral form: 1995  ACC Scientific Session

Principal Investigator

Sub Investigator

Services Offered: AHI & TCC